Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
AN EXPLORATORY HALOPERIDOL-CONTROLLED DOSE-FINDING STUDY OF ZIPRASIDONE IN HOSPITALIZED-PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER
Autore:
GOFF DC; POSEVER T; HERZ L; SIMMONS J; KLETTI N; LAPIERRE K; WILNER KD; LAW CG; KO GN;
Indirizzi:
ERICH LINDEMANN MENTAL HLTH CTR,FREEDOM TRAIL CLIN,25 STANIFORD ST BOSTON MA 02114 MASSACHUSETTS GEN HOSP,PSYCHOT DISORDERS PROGRAM BOSTON MA 02114 TUFTS UNIV NEW ENGLAND MED CTR BOSTON MA 02111 BEDFORD VA HOSP BEDFORD MA 00000 TEWKSBURY STATE HOSP TEWSKBURY MA 00000 UNIV MASSACHUSETTS,MED CTR WORCESTER MA 00000 PFIZER INC,PFIZER CENT RES GROTON CT 06340
Titolo Testata:
Journal of clinical psychopharmacology
fascicolo: 4, volume: 18, anno: 1998,
pagine: 296 - 304
SICI:
0271-0749(1998)18:4<296:AEHDSO>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; ANTIPSYCHOTIC-DRUGS; RECEPTOR ANTAGONIST; DOPAMINE; OCCUPANCY; D-2; CP-88,059-01; ICI-169,369; RACLOPRIDE; RITANSERIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
17
Recensione:
Indirizzi per estratti:
Citazione:
D.C. Goff et al., "AN EXPLORATORY HALOPERIDOL-CONTROLLED DOSE-FINDING STUDY OF ZIPRASIDONE IN HOSPITALIZED-PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER", Journal of clinical psychopharmacology, 18(4), 1998, pp. 296-304

Abstract

Ninety patients with schizophrenia or schizoaffective disorder according to DSM-III-R criteria participated in this double-blind, exploratory, dose-ranging trial. After a single-blind washout period of 4 to 7 days, patients were randomly assigned to receive one of four fixed doses of the new antipsychotic, ziprasidone 4 (N = 19), 10 (N = 17), 40 (N = 17), or 160 (N = 20) mg/day or haloperidol 15 mg/day (N = 17) for 4 weeks. A dose-response relationship among ziprasidone groups was established for improvements in Clinical Global impression Severity (CGI-S) score (p = 0.002) but not in Brief Psychiatric Rating Scale (BPRS) total score (p = 0.08). The intent-to-treat analysis of mean changes from baseline in the BPRS total, BPRS Psychosis core, and CGI-S scores demonstrated that ziprasidone 160 mg/day was comparable with haloperidol in reducing overall psychopathology and positive symptoms and was superior to ziprasidone 4 mg/day. Despite the small sample size and short duration of the trial, the improvement in CGI-S with both ziprasidone 160 mg/day and haloperidol 15 mg/day was statistically significantly greater than with ziprasidone 4 mg/day (p = 0.001 and p = 0.005, respectively). The percentage of patients classified as responders on both the BPRS total (greater than or equal to 30% improvement) and CGI-Improvement (score of 1 or 2) scales in the ziprasidone 160 mg/day groupwas similar to that in the haloperidol group and nonsignificantly greater than that in the ziprasidone 4 mg/day group. On all assessments of clinical efficacy, the improvements associated with ziprasidone 4 mg/day, 10 mg/day, and 40 mg/day were similar. Concomitant benztropine use at any time during the study was less frequent with ziprasidone 160mg/day (15%) than with haloperidol (53%). Haloperidol was associated with a sustained hyperprolactinemia, unlike ziprasidone, where only transient elevations in prolactin that returned to normal within the dosing interval were observed. Ziprasidone was well tolerated, and the incidence of adverse events was similar in all groups. The results of this study suggest that ziprasidone 160 mg/day is as effective as haloperidol 15 mg/day in reducing overall psychopathology and positive symptoms of an acute exacerbation of schizophrenia or schizoaffective disorder but has a lower potential to induce extrapyramidal symptoms.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:12:25